Sandra Till, DO
Critical Care Medicine · Scottsdale, AZNPI 1164658761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $932, 6.2 times the $150 reported in 2019.
Across 125 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$436
- Insmed, Inc.$362
- Boehringer Ingelheim$231
- AstraZeneca$225
- Intuitive Surgical$225
- Abiomed$173
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,20399%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $436 |
| Insmed, Inc. | 11 | $362 |
| Boehringer Ingelheim | 9 | $231 |
| AstraZeneca | 6 | $225 |
| Intuitive Surgical | 1 | $225 |
| Abiomed | 4 | $173 |
| Penumbra, Inc. | 1 | $166 |
| Grifols USA, LLC | 7 | $164 |
| Mylan Specialty L.p. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Actelion Pharmaceuticals US, Inc. | 3 | $93 |
| United Therapeutics Corporation | 4 | $84 |
| Electromed, Inc. | 9 | $83 |
| Merck | 4 | $78 |
| Viatris Specialty LLC | 3 | $77 |
| Amgen | 4 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $72 |
| Sanofi | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| CSL Behring | 2 | $48 |
| Pulmonx Corporation | 2 | $42 |
| Philips North America LLC | 2 | $42 |
| Inspire Medical Systems, Inc. | 2 | $38 |
| Advanced Respiratory, Inc | 2 | $36 |
| Verona Pharma, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $28 |
| Vifor Pharma, Inc. | 1 | $22 |
| CMP Pharma, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Baxter Healthcare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$225
- Indigo System$166
- Arikayce$133
- Impella$117
- TAGRISSO$116
How this compares
$3,223 in reported general payments places this provider in the 85th percentile of 175 critical care medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $131,074 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $21,018 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $19,968 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,835 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $5,853 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $4,319 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $2,236 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,298 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 16 | $907 |
| Ventolin HfaAlbuterol Sulfate | 14 | $776 |
| Azelastine Hcl | 18 | $599 |
| Fluconazole | 19 | $539 |
| Azithromycin | 39 | $358 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $292 |
| Montelukast Sodium | 35 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $436 | $157,877219 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $225 | $26,87144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 critical care medicine providers in Arizona.
Other critical care medicine in Scottsdale
- Akshay MuralidharScottsdale$44K
- Rodrigo Cartin-CebaScottsdale$18K
- Reena BansalScottsdale$10K
- Kenneth SakataScottsdale$4K
- Heemesh SethScottsdale$4K
- Aditya GuptaScottsdale$3K
- Pritesh PatelScottsdale$3K
- Benjamin CantrillScottsdale$2K
- Randy WeismanScottsdale$2K
- Harseerat RataulScottsdale$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.